KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Astrana Health (ASTH) EBITDA (2016 - 2025)

Historic EBITDA for Astrana Health (ASTH) over the last 17 years, with Q3 2025 value amounting to $19.2 million.

  • Astrana Health's EBITDA fell 3241.86% to $19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.9 million, marking a year-over-year decrease of 2820.55%. This contributed to the annual value of $89.4 million for FY2024, which is 559.84% up from last year.
  • As of Q3 2025, Astrana Health's EBITDA stood at $19.2 million, which was down 3241.86% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, Astrana Health's EBITDA ranged from a high of $53.2 million in Q3 2021 and a low of -$3.9 million during Q4 2023
  • Moreover, its 5-year median value for EBITDA was $21.8 million (2021), whereas its average is $23.0 million.
  • In the last 5 years, Astrana Health's EBITDA surged by 45960.85% in 2022 and then tumbled by 13076.31% in 2023.
  • Quarter analysis of 5 years shows Astrana Health's EBITDA stood at $2.2 million in 2021, then skyrocketed by 459.61% to $12.6 million in 2022, then plummeted by 130.76% to -$3.9 million in 2023, then surged by 118.6% to $720000.0 in 2024, then skyrocketed by 2568.06% to $19.2 million in 2025.
  • Its EBITDA stands at $19.2 million for Q3 2025, versus $20.3 million for Q2 2025 and $20.6 million for Q1 2025.